ELK GROVE VILLAGE, IL – Jan. 4, 2024 – Orsini Specialty Pharmacy (“Orsini”) has been selected by AstraZeneca and Ionis as the exclusive specialty...
ADZYNMA (ADAMTS13, recombinant-krhn) is now in stock with Orsini and ready for distribution. Orsini is the exclusive specialty pharmacy partner for...
ELK GROVE VILLAGE, Ill., Nov. 20, 2023 /PRNewswire/ -- Orsini Specialty Pharmacy has been selected by Takeda Pharmaceuticals as the exclusive specialty...
Orsini Specialty Pharmacy has been selected by Amicus Therapeutics to dispense Pombiliti™ (cipaglucosidase alfa-atga) and Opfolda™ (miglustat), a...
ELK GROVE VILLAGE, IL – August 2023 – Orsini Specialty Pharmacy ("Orsini"), a leading independent specialty pharmacy focused on rare diseases and gene...
ELK GROVE VILLAGE, IL – Aug. 23, 2023 – Orsini Specialty Pharmacy ("Orsini"), a leading independent specialty pharmacy focused on rare diseases and...
Orsini Specialty Pharmacy, a leading independent specialty pharmacy focused on rare diseases and gene therapies, announced that BioMarin Pharmaceutical...
The complexities of managing the care of a rare disease patient are tremendous. Several models of care are efficient when optimizing patient care...
Orsini Specialty Pharmacy, a leading independent specialty pharmacy focused on rare diseases and gene therapies, has been selected by Sarepta...
Orsini Specialty Pharmacy, a leader in rare diseases and gene therapies, announced that Aimmune Therapeutics, a Nestle Health Science Company, has...
Orsini is a leading independent national specialty pharmacy accredited by ACHC, JCAHO, URAC, and VIPPS. The services we provide allow patients, physicians, payors, and manufacturers to improve care, simplify processes, and achieve better outcomes.
Orsini selected as the exclusive specialty pharmacy for WAINUA (eplontersen) for adults with hereditary transthyretin-mediated amyloid polyneuropathy
Now In Stock: ADZYNMA (ADAMTS13, recombinant-krhn), for patients with cTTP
Orsini Specialty Pharmacy Selected as Distribution Partner for Adzynma (ADAMTS13, recombinant-krhn), a Newly Approved Treatment for an Ultra-Rare Blood Clotting Disorder
Orsini Specialty Pharmacy Partners with Amicus Therapeutics to Dispense New Therapy for the Treatment of Late-Onset Pompe Disease
Orsini Specialty Pharmacy Names Darin DeCarlo Chief Growth Officer